Published in Vaccine on April 05, 2011
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol (2011) 2.53
Plasmodium falciparum variant surface antigen expression varies between isolates causing severe and nonsevere malaria and is modified by acquired immunity. J Immunol (2002) 2.39
Durable human memory T cells quantifiable by cultured enzyme-linked immunospot assays are induced by heterologous prime boost immunization and correlate with protection against malaria. J Immunol (2005) 2.19
Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J (2005) 2.06
Malaria-induced acquisition of antibodies to Plasmodium falciparum variant surface antigens. Infect Immun (2002) 2.00
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine (2010) 1.99
Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J (2006) 1.94
A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar J (2012) 1.87
Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun (2005) 1.83
Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis (2011) 1.74
Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine (2007) 1.66
Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun (2004) 1.60
Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or AS02. PLoS One (2008) 1.56
Three-year surveillance of intussusception in children in Switzerland. Pediatrics (2007) 1.45
Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun (2003) 1.44
Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine (2005) 1.33
Influenza vaccination among healthcare workers in a university children's hospital. Infect Control Hosp Epidemiol (2005) 1.32
New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis (2004) 1.29
A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines. Vaccine (2012) 1.25
Geographical and temporal conservation of antibody recognition of Plasmodium falciparum variant surface antigens. Infect Immun (2004) 1.24
Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities. Vaccine (2013) 1.21
Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine (2009) 1.19
Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat? Pediatr Infect Dis J (2012) 1.19
Bone marrow suppression and severe anaemia associated with persistent Plasmodium falciparum infection in African children with microscopically undetectable parasitaemia. Malar J (2005) 1.18
Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial. Vaccine (2006) 1.16
Prospective surveillance of hospitalisations associated with varicella-zoster virus infections in children and adolescents. Eur J Pediatr (2005) 1.14
Increased levels of inflammatory mediators in children with severe Plasmodium falciparum malaria with respiratory distress. J Infect Dis (2006) 1.13
How do physicians immunize their own children? Differences among pediatricians and nonpediatricians. Pediatrics (2005) 1.13
Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013. Pediatr Infect Dis J (2015) 1.12
The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine (2002) 1.11
Expression of variant surface antigens by Plasmodium falciparum parasites in the peripheral blood of clinically immune pregnant women indicates ongoing placental infection. Infect Immun (2003) 1.11
Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris. Vaccine (2008) 1.10
Standardised case definitions for adverse events following immunisation. Lancet (2013) 1.09
Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis (2005) 1.08
Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon. Vaccine (2010) 1.07
Intussusception: incidence and treatment-insights from the nationwide German surveillance. J Pediatr Gastroenterol Nutr (2011) 1.03
Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults. Malar J (2011) 1.03
Levels of soluble CD163 and severity of malaria in children in Ghana. Clin Vaccine Immunol (2008) 1.02
Vaccination policies for health-care workers in acute health-care facilities in Europe. Vaccine (2011) 1.02
Mannose-binding lectin is a disease modifier in clinical malaria and may function as opsonin for Plasmodium falciparum-infected erythrocytes. Infect Immun (2003) 1.01
Health burden of pertussis in infants and children. Pediatr Infect Dis J (2005) 0.99
Complement activation in Ghanaian children with severe Plasmodium falciparum malaria. Malar J (2007) 0.97
Differences in human antibody reactivity to Plasmodium falciparum variant surface antigens are dependent on age and malaria transmission intensity in northeastern Tanzania. Infect Immun (2008) 0.97
Artemisinin resistance on the Thai-Cambodian border. Lancet (2009) 0.97
Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection. Vaccine (2009) 0.96
All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization. Vaccine (2007) 0.95
Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data. Vaccine (2007) 0.94
Determination of serum antibody to Bordetella pertussis adenylate cyclase toxin in vaccinated and unvaccinated children and in children and adults with pertussis. Clin Infect Dis (2004) 0.94
Guidelines for collection, analysis and presentation of vaccine safety data in pre- and post-licensure clinical studies. Vaccine (2008) 0.94
Comparison of clinical characteristics of influenza and respiratory syncytial virus infection in hospitalised children and adolescents. Eur J Pediatr (2004) 0.93
Seroprevalence and immunization history of selected vaccine preventable diseases in medical students. Vaccine (2005) 0.93
Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis. Clin Vaccine Immunol (2010) 0.93
Transplacentally acquired immunoglobulin G antibodies against measles, mumps, rubella and varicella-zoster virus in preterm and full term newborns. Pediatr Infect Dis J (2004) 0.92
Prospective pertussis surveillance in Switzerland, 1991-2006. Vaccine (2011) 0.91
Comparative coverage of supplementary and universally recommended immunizations in children at 24 months of age. Pediatr Infect Dis J (2012) 0.91
The parental appraisal of the morbidity of diarrhea in infants and toddlers (PAMODI) survey. Clin Pediatr (Phila) (2008) 0.90
No temporal association between influenza outbreaks and invasive pneumococcal infections. Arch Dis Child (2007) 0.90
Antibody response to an eleven valent diphtheria- and tetanus-conjugated pneumococcal conjugate vaccine in Filipino infants. Pediatr Infect Dis J (2002) 0.90
Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr (2002) 0.90
Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults. PLoS One (2012) 0.89
A 4-year study on clinical characteristics of children hospitalized with rotavirus gastroenteritis. Eur J Pediatr (2009) 0.89
Metaanalysis of vaccine effectiveness in varicella outbreaks. Vaccine (2007) 0.88
Insights into deregulated TNF and IL-10 production in malaria: implications for understanding severe malarial anaemia. Malar J (2012) 0.88
The development of standardized case definitions and guidelines for adverse events following immunization. Vaccine (2007) 0.88
Etiology of aseptic meningitis, peripheral facial nerve palsy, and a combination of both in children. Pediatr Infect Dis J (2010) 0.87
European Malaria Vaccine Initiative: portfolio and perspectives for the future. Hum Vaccin (2010) 0.87
Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems. Vaccine (2008) 0.86
Acceptance and timeliness of standard vaccination in children with chronic neurological deficits in north-western Switzerland. Eur J Pediatr (2005) 0.86
Mycobacterium bohemicum--a cause of paediatric cervical lymphadenitis. Swiss Med Wkly (2004) 0.86
Toll-like receptor 9 (TLR9) polymorphism associated with symptomatic malaria: a cohort study. Malar J (2012) 0.86
Clinical findings and unusual epidemiologic characteristics of human metapneumovirus infections in children in the region of Basel, Switzerland. Eur J Pediatr (2007) 0.85
Rotavirus disease in Germany--a prospective survey of very severe cases. Pediatr Infect Dis J (2013) 0.85
Apnoea and bradycardia in preterm infants following immunisation with pentavalent or hexavalent vaccines. Eur J Pediatr (2005) 0.85
Economic evaluation of varicella vaccination in Swiss children and adolescents. Hum Vaccin (2009) 0.85
A multicenter, cross-sectional study on the prevalence and risk factors for nasal colonization with Staphylococcus aureus in patients admitted to children's hospitals in Switzerland. Clin Infect Dis (2008) 0.85
Early appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection? Clin Vaccine Immunol (2006) 0.84
Hypotonic-Hyporesponsive Episode (HHE) as an adverse event following immunization: case definition and guidelines for data collection, analysis, and presentation. Vaccine (2004) 0.84
MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines. Malar J (2012) 0.84
Template protocol for clinical trials investigating vaccines--focus on safety elements. Vaccine (2013) 0.84
Kinetics of maternally acquired anti-hepatitis A antibodies: prediction of waning based on maternal or cord blood antibody levels. Vaccine (2013) 0.84
Immune response to octavalent diphtheria- and tetanus-conjugated pneumococcal vaccines is serotype- and carrier-specific: the choice for a mixed carrier vaccine. Pediatr Infect Dis J (2002) 0.83
Malaria vaccine research and development: the role of the WHO MALVAC committee. Malar J (2013) 0.83
Elevated levels of nitric oxide and low levels of haptoglobin are associated with severe malarial anaemia in African children. Acta Trop (2002) 0.83
Adverse events following immunization: perception and evidence. Curr Opin Infect Dis (2007) 0.83
European Vaccine Initiative: lessons from developing malaria vaccines. Expert Rev Vaccines (2011) 0.83
The Brighton Collaboration: enhancing comparability of vaccine safety data. Pharmacoepidemiol Drug Saf (2003) 0.83
Standardized case definitions of adverse events following immunization (AEFI). Vaccine (2004) 0.83
Prospective surveillance of nosocomial viral infections during and after hospitalization at a university children's hospital. Pediatr Infect Dis J (2010) 0.82
Prospective study on central venous line associated bloodstream infections. Arch Dis Child (2011) 0.82
Severe malaria in west African children. Lancet (2003) 0.82
Incidence and Outcome of Group B Streptococcal Sepsis in Infants in Switzerland. Pediatr Infect Dis J (2016) 0.81
Compliance with antenatal screening for hepatitis B surface antigen carrier status in pregnant women and consecutive procedures in exposed newborns. Eur J Pediatr (2004) 0.81
Fever following immunization. Expert Rev Vaccines (2005) 0.81
Priorities in research and development of vaccines against Plasmodium vivax malaria. Vaccine (2009) 0.81
Prevalence of nosocomial infections in Swiss children's hospitals. Infect Control Hosp Epidemiol (2004) 0.81
Human leukocyte antigen class I polymorphisms influence the mild clinical manifestation of Plasmodium falciparum infection in Ghanaian children. Hum Immunol (2011) 0.81